Balance Sheet Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-11 pm EDT			5-day change	1st Jan Change
112.93 ^USD	-1.59%		-5.50%	-10.34%

11:05am	Ascendis Pharma Gets FDA Orphan Drug Designation for Hypoparathyroidism Treatment	MT
Sep. 11	Ascendis Pharma Gets Orphan Drug Exclusivity for Hormone Treatment Yorvipath in U.S.	DJ

2c4279333fe7e822e0641720.N7W8aX-kxZ2K7T0Id-GGzA3oTzs0nNwepnOvj-sC1NA.D8_WARuTsuzigERKDZXXhGiFLH5Q6ul34UD146pw4b1jmPYvD-L9rd-kSg

Published financial data: ASCENDIS PHARMA A/S

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	13.38M	6.95M	7.78M	51.17M	267M
Total Revenues	13.38M	6.95M	7.78M	51.17M	267M
Cost of Goods Sold, Total	-	-	3.52M	12.14M	44.4M
Gross Profit	13.38M	6.95M	4.26M	39.04M	222M
Selling General & Admin Expenses, Total	48.47M	76.67M	160M	221M	264M
R&D Expenses	192M	261M	296M	380M	413M
Other Operating Expenses, Total	240M	338M	456M	601M	678M
Operating Income	-227M	-331M	-452M	-562M	-456M
Interest Expense, Total	-1.22M	-1.92M	-3.91M	-30.68M	-44.06M
Interest And Investment Income	10.06M	1.81M	692K	7.43M	16.86M
Net Interest Expenses	8.84M	-106K	-3.22M	-23.26M	-27.21M
Income (Loss) On Equity Invest.	-8.11M	-9.52M	12.04M	-17.7M	-18.4M
Currency Exchange Gains (Loss)	7.75M	-78.92M	59.03M	44.76M	12.35M
Other Non Operating Income (Expenses)	-	-	-	-19.8M	14.65M
EBT, Excl. Unusual Items	-218M	-419M	-384M	-578M	-474M
EBT, Incl. Unusual Items	-218M	-419M	-384M	-578M	-474M
Income Tax Expense	-234K	-219K	-367K	5.38M	7.3M
Earnings From Continuing Operations	-218M	-419M	-384M	-583M	-481M
Net Income to Company	-218M	-419M	-384M	-583M	-481M
Net Income - (IS)	-218M	-419M	-384M	-583M	-481M
Net Income to Common Incl Extra Items	-218M	-419M	-384M	-583M	-481M
Net Income to Common Excl. Extra Items	-218M	-419M	-384M	-583M	-481M
Per Share Items
Net EPS - Basic	-4.69	-8.28	-7	-10.4	-8.55
Basic EPS - Continuing Operations	-4.69	-8.28	-7	-10.4	-8.55
Basic Weighted Average Shares Outstanding	46.51M	50.62M	54.77M	56.07M	56.29M
Net EPS - Diluted	-4.69	-8.28	-7	-10.4	-8.55
Diluted EPS - Continuing Operations	-4.69	-8.28	-7	-10.4	-8.55
Diluted Weighted Average Shares Outstanding	46.51M	50.62M	54.77M	56.07M	56.29M
Normalized Basic EPS	-2.93	-5.18	-4.38	-6.44	-5.26
Normalized Diluted EPS	-2.93	-5.18	-4.38	-6.44	-5.26
American Depositary Receipts Ratio (ADR)	1	1	1	1	1
Supplemental Items
EBITDA	-225M	-328M	-448M	-556M	-449M
EBITA	-227M	-331M	-452M	-562M	-456M
EBIT	-227M	-331M	-452M	-562M	-456M
EBITDAR	-225M	-328M	-448M	-556M	-449M
Effective Tax Rate - (Ratio)	0.11	0.05	0.1	-0.93	-1.54
Current Foreign Taxes	-234K	-219K	-367K	-	-
Total Current Taxes	-234K	-219K	-367K	5.38M	1.47M
Total Deferred Taxes	-	-	-	-	5.83M
Normalized Net Income	-136M	-262M	-240M	-361M	-296M
Interest on Long-Term Debt	1.01M	1.62M	3.4M	3.84M	3.58M
Supplemental Operating Expense Items
General and Administrative Expenses	48.47M	-	-	-	-
Research And Development Expense From Footnotes	192M	261M	296M	380M	413M
Net Rental Expense, Total	202K	470K	186K	280K	353K
Imputed Operating Lease Interest Expense	-	112K	59.1K	224K	216K
Imputed Operating Lease Depreciation	-	358K	127K	55.89K	137K
Stock-Based Comp., R&D Exp. (Total)	22.36M	33M	37.4M	-	-
Stock-Based Comp., G&A Exp. (Total)	15.13M	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	-	20.2M	29.4M	-	-
Stock-Based Comp., Other (Total)	-	-	30K	64.18M	66.66M
Total Stock-Based Compensation	37.49M	53.2M	66.83M	64.18M	66.66M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	598M	585M	446M	445M	392M
Short Term Investments	-	134M	236M	291M	7.28M
Total Cash And Short Term Investments	598M	719M	682M	735M	399M
Accounts Receivable, Total	-	387K	2.2M	11.91M	35.87M
Other Receivables	5.41M	6.96M	20.99M	13.72M	19.9M
Total Receivables	5.41M	7.34M	23.19M	25.63M	55.77M
Inventory	-	-	75.4M	131M	209M
Prepaid Expenses	7.65M	13.99M	25.23M	31.72M	38.58M
Total Current Assets	611M	740M	806M	923M	703M
Gross Property Plant And Equipment	56.39M	128M	160M	176M	182M
Accumulated Depreciation	-11.32M	-19.79M	-33.92M	-46.65M	-71.52M
Net Property Plant And Equipment	45.07M	108M	126M	129M	111M
Long-term Investments	15.54M	124M	146M	30.42M	5.69M
Goodwill	3.5M	3.5M	3.5M	3.5M	3.5M
Other Intangibles, Total	-	2.22M	1.78M	1.33M	924K
Other Long-Term Assets, Total	1.46M	1.38M	1.81M	1.92M	2.13M
Total Assets	677M	980M	1.08B	1.09B	826M
Liabilities
Accounts Payable, Total	27.76M	21.9M	59.42M	101M	94.57M
Accrued Expenses, Total	13.35M	23.38M	29.95M	31.99M	41.18M
Current Portion of Long-Term Debt	-	-	-	11.42M	11.23M
Current Portion of Leases	5.9M	6.86M	7M	14M	14.17M
Current Income Taxes Payable	119K	301K	198K	5.49M	2.3M
Unearned Revenue Current, Total	858K	363K	2.6M	-	1.18M
Other Current Liabilities	-	-	1.19M	7.34M	32.72M
Total Current Liabilities	47.99M	52.8M	100M	171M	197M
Long-Term Debt	-	-	-	388M	534M
Long-Term Leases	30.72M	85.12M	97.97M	95.2M	84.62M
Unearned Revenue Non Current	-	-	2.96M	14.21M	5.95M
Deferred Tax Liability Non Current	-	-	-	-	5.83M
Other Non Current Liabilities	908K	3.16M	-	158M	143M
Total Liabilities	79.62M	141M	201M	826M	971M
Common Stock, Total	6.44M	7.22M	7.65M	7.68M	7.75M
Additional Paid In Capital	1.12B	1.73B	2.11B	2.11B	2.12B
Retained Earnings	-611M	-1.03B	-1.41B	-1.86B	-2.28B
Treasury Stock	-	-	-21.6M	-149K	-146K
Comprehensive Income and Other	79.9M	133M	204M	3.45M	721K
Total Common Equity	597M	839M	884M	263M	-146M
Total Equity	597M	839M	884M	263M	-146M
Total Liabilities And Equity	677M	980M	1.08B	1.09B	826M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	47.99M	53.75M	56.78M	56.04M	56.61M
ECS Total Common Shares Outstanding	47.99M	53.75M	56.78M	56.04M	56.61M
Book Value / Share	12.44	15.6	15.56	4.7	-2.57
Tangible Book Value	594M	833M	878M	259M	-150M
Tangible Book Value Per Share	12.37	15.5	15.47	4.61	-2.65
Total Debt	36.62M	91.98M	105M	508M	644M
Net Debt	-561M	-742M	-685M	-235M	245M
Debt Equivalent Oper. Leases	1.62M	3.76M	1.49M	2.24M	2.82M
Equity Method Investments, Total	15.54M	9.18M	38.34M	22.93M	5.69M
Account Code - Inventory Valuation	3	3	3	3	3
Inventories - Raw Materials, Total	-	-	2.25M	9.62M	18.57M
Inventories - Work In Process, Total	-	-	68.86M	113M	171M
Inventories - Finished Goods, Total	-	-	4.29M	8.17M	19.34M
Machinery, Total	11.98M	19.8M	25.77M	36.15M	38.86M
Full Time Employees	330	482	639	797	879

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	-218M	-419M	-384M	-583M	-481M
Depreciation & Amortization - CF	6.69M	9.45M	14.95M	17.51M	18.43M
Depreciation & Amortization, Total	6.69M	9.45M	14.95M	17.51M	18.43M
Amortization of Deferred Charges, Total - (CF)	-	-	445K	444K	483K
(Gain) Loss From Sale Of Asset	-	-	-	22K	5K
Asset Writedown & Restructuring Costs	-	-	-	-	7.83M
(Income) Loss On Equity Investments - (CF)	8.11M	9.52M	-12.04M	17.7M	18.4M
Stock-Based Compensation (CF)	37.49M	53.17M	66.83M	64.18M	66.66M
Other Operating Activities, Total	-14.28M	76.23M	-55.34M	6.26M	2.07M
Change In Accounts Receivable	-1.88M	-2M	-6.66M	-11.53M	-32.77M
Change In Inventories	-	-	-75.4M	-55.27M	-78.26M
Change In Accounts Payable	7.53M	7.88M	39.19M	45.94M	3.55M
Change in Unearned Revenues	-6.04M	-495K	5.2M	8.65M	-7.08M
Change in Other Net Operating Assets	4.46M	-6.36M	-11.24M	-6.41M	14.77M
Cash from Operations	-176M	-272M	-418M	-496M	-467M
Capital Expenditure	-5.16M	-19.86M	-23.7M	-14.49M	-2.44M
Sale of Property, Plant, and Equipment	-	-	-	-	51K
Sale (Purchase) of Intangible assets	-	-1.69M	-530K	-	-
Investment in Marketable and Equity Securities, Total	-	-275M	-86.34M	66.69M	289M
Other Investing Activities, Total	-	5.05M	-	9.54M	-
Cash from Investing	-5.16M	-291M	-111M	61.73M	286M
Long-Term Debt Issued, Total	-	-	-	503M	136M
Total Debt Issued	-	-	-	503M	136M
Long-Term Debt Repaid, Total	-4.04M	-4.77M	-6.43M	-6.36M	-10.44M
Total Debt Repaid	-4.04M	-4.77M	-6.43M	-6.36M	-10.44M
Issuance of Common Stock	529M	639M	379M	5.15M	10.29M
Repurchase of Common Stock	-	-	-21.6M	-105M	-1.81M
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-31.7M	-31.37M	-	-	-
Cash from Financing	494M	603M	351M	397M	134M
Foreign Exchange Rate Adjustments	7.75M	-53.49M	38.59M	35.69M	-6.01M
Net Change in Cash	320M	-13.59M	-138M	-1.5M	-52.6M
Supplemental Items
Cash Interest Paid	717K	1.5M	1.84M	9.29M	15.67M
Cash Income Tax Paid (Refund)	279K	-1.1M	-152K	3K	4.47M
Levered Free Cash Flow	-98.29M	-171M	-282M	-314M	-318M
Unlevered Free Cash Flow	-97.53M	-170M	-279M	-295M	-291M
Change In Net Working Capital	-5.16M	4.42M	55.07M	11.7M	89.17M
Net Debt Issued / Repaid	-4.04M	-4.77M	-6.43M	497M	126M

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	-28.46	-24.95	-27.35	-32.29	-29.73
Return on Total Capital	-31.01	-26.42	-29.42	-39.89	-44.83
Return On Equity %	-49.71	-58.36	-44.54	-101.69	-818.43
Return on Common Equity	-49.71	-58.36	-44.54	-101.69	-818.43
Margin Analysis
Gross Profit Margin %	100	100	54.71	76.28	83.36
SG&A Margin	362.41	1.1K	2.06K	432.3	99.13
EBITDA Margin %	-1.68K	-4.72K	-5.76K	-1.09K	-168.34
EBITA Margin %	-1.7K	-4.76K	-5.81K	-1.1K	-170.79
EBIT Margin %	-1.7K	-4.76K	-5.81K	-1.1K	-170.79
Income From Continuing Operations Margin %	-1.63K	-6.03K	-4.93K	-1.14K	-180.51
Net Income Margin %	-1.63K	-6.03K	-4.93K	-1.14K	-180.51
Net Avail. For Common Margin %	-1.63K	-6.03K	-4.93K	-1.14K	-180.51
Normalized Net Income Margin	-1.02K	-3.77K	-3.09K	-705.7	-111.11
Levered Free Cash Flow Margin	-734.87	-2.46K	-3.62K	-614.31	-119.34
Unlevered Free Cash Flow Margin	-729.17	-2.44K	-3.59K	-576.84	-109.01
Asset Turnover
Asset Turnover	0.03	0.01	0.01	0.05	0.28
Fixed Assets Turnover	0.54	0.09	0.07	0.4	2.23
Receivables Turnover (Average Receivables)	-	11.68	6.01	7.25	11.16
Inventory Turnover (Average Inventory)	-	-	-	0.12	0.26
Short Term Liquidity
Current Ratio	12.74	14.02	8.03	5.39	3.56
Quick Ratio	12.58	13.75	7.03	4.44	2.31
Operating Cash Flow to Current Liabilities	-3.67	-5.14	-4.16	-2.89	-2.37
Days Sales Outstanding (Average Receivables)	-	31.35	60.7	50.32	32.7
Days Outstanding Inventory (Average Inventory)	-	-	-	3.1K	1.4K
Average Days Payable Outstanding	-	-	-	434.42	291.04
Cash Conversion Cycle (Average Days)	-	-	-	2.71K	1.14K
Long Term Solvency
Total Debt/Equity	6.13	10.97	11.88	193.04	-442.2
Total Debt / Total Capital	5.78	9.88	10.62	65.88	129.22
LT Debt/Equity	5.14	10.15	11.09	183.39	-424.76
Long-Term Debt / Total Capital	4.85	9.15	9.91	62.58	124.13
Total Liabilities / Total Assets	11.76	14.4	18.55	75.83	117.65
EBIT / Interest Expense	-185.68	-172.38	-115.52	-18.31	-10.34
EBITDA / Interest Expense	-180.2	-167.45	-111.7	-17.74	-9.92
(EBITDA - Capex) / Interest Expense	-184.43	-177.81	-117.76	-18.21	-9.98
Total Debt / EBITDA	-0.17	-0.29	-0.24	-0.93	-1.47
Net Debt / EBITDA	2.55	2.31	1.57	0.43	-0.56
Total Debt / (EBITDA - Capex)	-0.16	-0.27	-0.23	-0.91	-1.47
Net Debt / (EBITDA - Capex)	2.49	2.18	1.49	0.42	-0.56
Growth Over Prior Year